Enzon Pharmaceuticals Inc (NASDAQ:ENZN)

0.98
Data as of Oct 20
 +0.017 / +1.77%
Today’s Change
0.78
Today|||52-Week Range
1.83
-15.52%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$42.5M

Company Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. The company engages in the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Its drug-development programs utilize two platforms such as customized PEGylation linker technology and third-generation mRNA-targeting agents utilizing the locked nucleic acid technology. The company receives royalties on marketed products that utilize PEGylation platform, including PegIntron, Sylatron, Macugen, CIMZIA, OMONTYS, Oncaspar and Adagen. Enzon Pharmaceuticals was founded by Abraham Abuchowski on September 17, 1981 and is headquartered in Piscataway, NJ.

Contact Information

Enzon Pharmaceuticals, Inc.
20 Kingsbridge Road
Piscataway New Jersey 08854
P:(732) 980-4500
Investor Relations:

Employees

Shareholders

Other institutional51.51%
Individual stakeholders23.21%
Mutual fund holders11.89%

Top Executives

George W. HebardChief Executive & Operating Officer
Richard L. FeinsteinChief Financial Officer & Vice President-Finance
Andrew D. RackearSecretary, Chief Compliance Officer & VP

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.